Filing Flows › Avita Medical (RCEL) › Q3 2026 › vs Q2 2026
Avita Medical (RCEL) Q3 2026 vs Q2 2026 (quarter over quarter)
Avita Medical's revenue rose $4.4M (+20%) from $21.7M in Q2 2026 to $26.1M in Q3 2026.
Avita Medical, Q3 2026: revenue $26.1M (+53% year over year), operating margin -10.1%, net loss $6.2M, operating cash flow −$710K. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $26.1M | $21.7M | $4.4M | +20% |
| Net loss | $6.2M | $7.7M | −$1.4M | -19% |
| Costs & expenses | $32.3M | $29.4M | $3.0M | +10% |
| Operating costs | $28.7M | $28.6M | $186K | +0.7% |
| Interest & other, net | $3.5M | $775K | $2.8M | +355% |
| Income tax | $65K | $33K | $32K | +97% |
| Cost of revenue | $4.2M | $3.9M | $238K | +6% |
| Research & development | $4.7M | $5.1M | −$381K | -8% |
| Sales & marketing | $13.6M | $13.6M | −$7K | -0.1% |
| General & admin | $6.3M | $6.0M | $336K | +6% |
| Operating cash sources | $6.2M | $7.7M | −$1.4M | -19% |
| Depreciation & amortization | $592K | $605K | −$13K | -2% |
| Share-based compensation | $1.7M | $2.0M | −$320K | -16% |
| Working capital & other | $3.3M | $1.6M | $1.7M | +107% |
| Cash used in operations | $710K | $3.5M | −$2.8M | -80% |
| Net loss absorbed | $6.2M | $7.7M | −$1.4M | -19% |
Questions
How much did Avita Medical's revenue grow quarter over quarter in Q3 2026?
Avita Medical's revenue rose $4.4M (+20%) from $21.7M in Q2 2026 to $26.1M in Q3 2026.